Horizon Pharma

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Wilmington, Delaware--(Newsfile Corp. - December 12, 2022) - Rigrodsky Law, P.A. is investigating Horizon Therapeutics Public Limited Company ("Horizon") (NASDAQ GS: HZNP) regarding possible breaches of fiduciary duties and other violations of law related to Horizon's agreement to be acquired by Amgen Inc. Under the terms of the agreement, Horizon's shareholders will receive $116.50 per share.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-horizon-therapeutics-public-limited-company.To contact Seth D. Rigrodsky or Gina M.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Horizon Therapeutics Public Limited Company Buyout

Amgen

Amgen Inc. said Monday that it's acquiring Dublin-based Horizon Therapeutics in a roughly $28 billion deal that is the biggest in the healthcare sector in 2022.

Amgen wins battle for Horizon Therapeutics, bolstering its rare-disease portfolio

Horizon is the largest disclosed holding of John Paulson's family office Paulson & Co., according to Forbes.

Billionaire John Paulson is reportedly set to reap $500 million from Amgen's huge deal to acquire Horizon Therapeutics

Amgen is acquiring Horizon Therapeutics for $27.8 billion. The deal immediately adds $3.7 billion in annual revenue.

Horizon Therapeutics Acquisition: A Good Deal For Amgen Investors

Coupa Software

iShares North American Tech-Software ETF

Johnson & Johnson

JPMorgan Chase & Co

Splunk

Two major deals in the biotech and software industry were inked this weekend.

The Return of "Merger Monday"

Amgen Inc. will acquire Horizon Therapeutics Public Limited Company for $116.50 per share in an all-cash transaction. This is a suboptimal exit for Horizon shareholders, but we should acknowledge the difficult market conditions.

What Amgen Is Getting Through The Acquisition Of Horizon Therapeutics

Sales of Horizon's thyroid-eye disease drug Tepezza have plateaued, a challenge its new owner will need to contend with.

First Test for Amgen: Fix Horizon's Growth Problem

Consensus is currently for a 50 basis point (bps) hike mid-week, which will bring the Fed funds rate over +4% for the first time in 15 years.

Busy Week Highlighted by Next Fed Rate Move

Hedge fund billionaire John Paulson stands to reap about $500 million if Amgen's deal for Horizon goes through. It's the latest victory for the man who shot to fame for his big bet during the subprime crisis.

Billionaire John Paulson Stands To Make $500 Million From Horizon's Sale To Amgen

Amgen's planned acquisition of Horizon could close in the first half of next year.

Why Horizon Therapeutics Stock Is Soaring Today

Amgen Inc. announced on Monday that it will acquire Horizon Therapeutics for $26 billion to further grow the company's medical legacy. Horizon's best-selling drug is Tepezza.

Amgen to buy Horizon Therapeutics for $26.4B

Horizon Therapeutics (NASDAQ: HZNP ) stock is up 15% today on news that pharmaceutical giant Amgen (NASDAQ: AMGN ) will acquire the Ireland-based company for $27.8 billion. The acquisition of Horizon Therapeutics is one of the biggest deals in the healthcare space this year, according to industry data.

Horizon Therapeutics (HZNP) Stock Pops on HUGE Amgen Deal

The shares of Horizon Therapeutics PLC (NASDAQ:HZNP) are up 14.9% at $111.75 this morning, following reports that Amgen (AMGN) will buy the biopharmaceutical company in a deal worth roughly $26.4 billion.

$26.4 Billion Amgen Buyout Sends Horizon Stock Soaring

Amgen announced a $28.3 billion plan to acquire Horizon Therapeutics on Monday, leading HZNP stock to soar higher. The post Amgen To Buy Rare Diseases Drugmaker Horizon Therapeutics In $28.3 Billion Deal appeared first on Investor's Business Daily.

Amgen To Buy Rare Diseases Drugmaker Horizon Therapeutics In $28.3 Billion Deal

Find out which companies are attracting interest from prospective buyers.

These 2 Nasdaq Stocks Are Soaring on Merger News

Amgen reaches a deal to buy drug company Horizon Therapeutics for $116.50 a share in cash.

Amgen to Buy Horizon Therapeutics

US biotechnology giant Amgen, Inc confirmed weekend speculation that it will be acquiring Horizon Therapeutics by formally unveiling a US$26.4bn swoop for the rare diseases drug maker. This will be the most significant transaction in Amgen's history and will give the company access to Horizon's blockbuster drug, Tepezza, which is used to treat thyroid eye disease.

Amgen confirms US$26bn swoop for Horizon Therapeutics

Amgen (AMGN) announced it is buying Horizon Therapeutics (HZNP) for $26.4 billion. These are the details.

Amgen (AMGN) To Buy Horizon Therapeutics (HZNP) For $26.4 Billion

Amgen Inc. AMGN, -2.42% said Monday it has agreed to acquire Horizon Therapeutics Plc HZNP, +0.39% in an all-cash deal valued at $27.8 billion, confirming earlier reports and a deal that was first mooted in November. Under the terms of the deal, Amgen will pay $116,50 per each Horizon share owned, equal to a 47.9% premium over the stock's closing price on Nov. 29, the day before the deal was first announced.

Amgen confirms to acquire Horizon Therapeutics in cash deal valued at about $27.8 billion

Amgen to Buy Horizon Therapeutics for $116.50 a Share

Amgen Inc is set to buy biotech firm Horizon Therapeutics Plc at a valuation of about $26 billion in what would be its largest acquisition, Bloomberg News reported on Monday.

Amgen set to buy biotech firm Horizon at $26 bln valuation - Bloomberg News

Amgen Inc. is in advanced talks to buy drug company Horizon Therapeutics PLC, according to people familiar with the matter, in a takeover likely to be valued at well over $20 billion and mark the largest healthcare merger of the year.

Amgen reportedly in talks to buy Horizon Therapeutics

The U.S. biotech company was the last of three suitors standing in an auction for Horizon. A deal would likely be valued at well over $20 billion and mark the largest healthcare merger of the year.

Amgen Nears Deal to Buy Horizon Therapeutics

Sanofi

French health group Sanofi said on Sunday that it no longer intends to make an offer for biotech company Horizon Therapeutics Plc HZNP.O, leaving Amgen Inc as the only remaining bidder.

Sanofi Says it does not intend to make an offer for horizon, leaving Amgen as sole bidder

AbbVie

Celsius Holdings

Copa Hlds

Equinor

Genmab - ADR

Lattice Semiconductor

Monster Beverage

PepsiCo

Seagen

An array of top stocks in a wide variety of industries are building cup bases as the stock market recovers. The post Top Stocks In Multiple Industries Build Bases As Market Gains Strength appeared first on Investor's Business Daily.

Top Stocks In Multiple Industries Build Bases As Market Gains Strength

News for Horizon Pharma Stock (HZNP)